Johnson & Johnson Vaccine

According to a report in the New York Times, federal health officials have confirmed 28 rare cases of bleeding disorders among adults, including 6 among men, who have received Johnson & Johnson’s COVID-19 vaccine. Dr. Tom Shimabukuro, Assistant Director of Immunization Safety at the Centers for Disease Control and Prevention, presented the new cases at the CDC Advisory Group meeting on May 13.

People with rare but serious diseases often form blood clots in the brain, and the content of platelets is low, which are blood components that help blood clots. Shimabukuro said the disease is “a rare, clinically serious, and life-threatening disease.” After reports last month that six women who received the vaccine had the disease, federal health officials recommended that the vaccine be suspended pending investigation.

They cancelled the suspension after 10 days, warned of the possible risks on the vaccine label, and pointed out that there was a “possible” link between the vaccine and the disease. So far, 22 confirmed cases have been reported, including 6 females and 6 males. All are adults between the ages of 18 and 59, and they have been vaccinated before the national break. (It is reported that another 25-year-old male is undergoing clinical trials.) Three people died, four people stayed in the hospital and one person was in the intensive care unit.

Since the meeting last month, there have been no new reports of deaths. The overall risk is still very low. More than 9 million doses of Johnson & Johnson vaccine have been provided. There are 12.4 cases per million doses for women aged 30 to 39 and 9.4 per million doses for women aged 40 to 49. These two demographics seem to be the most dangerous demographically.

Men and women of all ages have fewer than 3 cases per million doses. Of the 28 confirmed cases, 12 were obese, 7 were hypertension, 3 were diabetes, and 3 were taking estrogen, although it is not clear whether these factors significantly increase the risk of this disease.

Leave a Reply

Your email address will not be published. Required fields are marked *